Provided are fetal tissue cells or a fetal tissue extract which can effectively prevent or treat bone disorders or diseases.

Provided herein arm, inter alia, methods, cell populations, and compositions for treating chronic kidney disease in subjects with a congenital anomaly of a kidney and/or urinary tract.

Provided herein arm, inter alia, methods, cell populations, and compositions for treating chronic kidney disease in subjects with a congenital anomaly of a kidney and/or urinary tract.

The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.

The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.

The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.

Disclosed is a method for inducing direct reprogramming of urine cells into renal progenitor cells and a pharmaceutical composition including the renal progenitor cells reprogrammed by the method for preventing or treating renal cell injury disease. The method can make the mass production of customized reprogrammed renal progenitor cells by using urine cells, which are somatic cells easily and repeatedly obtainable without inconvenience and pain and as such, can be applied to incurable disease fields expandable to the renal injury therapy and kidney regeneration fields and to the production of cell therapy products.

Disclosed is a method for inducing direct reprogramming of urine cells into renal progenitor cells and a pharmaceutical composition including the renal progenitor cells reprogrammed by the method for preventing or treating renal cell injury disease. The method can make the mass production of customized reprogrammed renal progenitor cells by using urine cells, which are somatic cells easily and repeatedly obtainable without inconvenience and pain and as such, can be applied to incurable disease fields expandable to the renal injury therapy and kidney regeneration fields and to the production of cell therapy products.

The present disclosure provides compositions and methods related to regulatable Cas systems. Such systems provide for ligand-dependent, modular and tunable Cas protein expression and activity.

The present disclosure provides compositions and methods related to regulatable Cas systems. Such systems provide for ligand-dependent, modular and tunable Cas protein expression and activity.